TransMedics Group (TMDX) Financials

TransMedics Group logo
$94.19 -2.24 (-2.33%)
As of 03:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for TransMedics Group

Annual Income Statements for TransMedics Group

This table shows TransMedics Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/28/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-34 -29 -44 -36 -25 35 190
Consolidated Net Income / (Loss)
-34 -29 -44 -36 -25 35 190
Net Income / (Loss) Continuing Operations
-34 -29 -44 -36 -25 35 190
Total Pre-Tax Income
-34 -29 -44 -36 -27 36 108
Total Operating Income
-30 -26 -39 -31 -29 37 109
Total Gross Profit
14 17 21 65 154 262 363
Total Revenue
24 26 30 93 242 442 605
Operating Revenue
24 26 30 93 242 442 605
Total Cost of Revenue
9.74 9.00 9.10 28 88 179 243
Operating Cost of Revenue
9.74 9.00 9.10 28 88 179 243
Total Operating Expenses
43 43 61 97 183 225 254
Selling, General & Admin Expense
24 24 38 70 120 169 185
Research & Development Expense
20 19 22 27 63 56 69
Total Other Income / (Expense), net
-3.90 -2.33 -4.75 -4.73 2.06 -1.72 -1.06
Interest Expense
4.35 3.99 3.87 3.73 11 14 14
Other Income / (Expense), net
0.45 1.65 -0.88 -1.00 13 13 13
Income Tax Expense
0.04 0.03 0.04 0.07 -1.64 0.32 -83
Basic Earnings per Share
($2.36) ($1.16) ($1.60) ($1.23) ($0.77) $1.07 $5.60
Weighted Average Basic Shares Outstanding
14.20M 24.70M 27.62M 29.56M 32.52M 33.23M 33.99M
Diluted Earnings per Share
($2.36) ($1.16) ($1.60) ($1.23) ($0.77) $1.01 $4.87
Weighted Average Diluted Shares Outstanding
14.20M 24.70M 27.62M 29.56M 32.52M 35.22M 40.54M
Weighted Average Basic & Diluted Shares Outstanding
14.20M 24.70M 27.96M 32.20M 32.72M 33.66M 34.30M
Cash Dividends to Common per Share
$0.00 $0.00 $0.00 - - $0.00 $0.00

Quarterly Income Statements for TransMedics Group

This table shows TransMedics Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
12 12 4.22 6.86 26 35 24 105 7.32 15 17
Consolidated Net Income / (Loss)
12 12 4.22 6.86 26 35 24 105 7.32 15 17
Net Income / (Loss) Continuing Operations
12 12 4.22 6.86 26 35 24 105 7.32 15 17
Total Pre-Tax Income
12 12 4.25 6.99 27 36 23 22 8.49 19 24
Total Operating Income
12 13 3.92 8.64 27 37 23 21 13 24 28
Total Gross Profit
60 69 61 72 88 97 85 93 101 113 119
Total Revenue
97 114 109 122 144 157 144 161 174 190 203
Operating Revenue
97 114 109 122 144 157 144 161 174 190 203
Total Cost of Revenue
37 45 48 50 55 61 59 67 73 77 84
Operating Cost of Revenue
37 45 48 50 55 61 59 67 73 77 84
Total Operating Expenses
48 57 57 63 61 60 61 72 88 89 91
Selling, General & Admin Expense
36 43 43 47 44 44 46 51 63 58 61
Research & Development Expense
11 14 14 16 17 16 15 21 25 32 29
Total Other Income / (Expense), net
-0.03 -0.36 0.32 -1.66 -0.77 -0.39 -0.27 0.36 -4.81 -4.33 -4.04
Interest Expense
3.60 3.62 3.62 3.57 3.46 3.48 3.49 3.35 7.17 7.23 7.27
Other Income / (Expense), net
3.57 3.27 3.94 1.92 2.69 3.09 3.22 3.71 2.36 2.89 3.23
Income Tax Expense
0.20 -0.04 0.03 0.13 0.99 1.28 -1.29 -84 1.17 4.72 7.03
Basic Earnings per Share
$0.37 $0.37 $0.13 $0.20 $0.76 $1.03 $0.71 $3.10 $0.21 $0.42 $0.49
Weighted Average Basic Shares Outstanding
32.76M 33.12M 33.44M 33.23M 33.72M 33.91M 34.11M 33.99M 34.38M 34.58M 34.69M
Diluted Earnings per Share
$0.35 $0.35 $0.12 $0.19 $0.70 $0.92 $0.66 $2.59 $0.20 $0.41 $0.46
Weighted Average Diluted Shares Outstanding
34.68M 35.29M 35.68M 35.22M 39.91M 40.56M 40.75M 40.54M 36.19M 40.71M 40.83M
Weighted Average Basic & Diluted Shares Outstanding
32.94M 33.36M 33.56M 33.66M 33.83M 34.09M 34.17M 34.30M 34.56M 34.68M 34.73M

Annual Cash Flow Statements for TransMedics Group

This table details how cash moves in and out of TransMedics Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/28/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-0.06 4.49 1.00 176 194 -58 152
Net Cash From Operating Activities
-32 -30 -29 -46 -13 49 193
Net Cash From Continuing Operating Activities
-32 -30 -29 -46 -13 49 193
Net Income / (Loss) Continuing Operations
-34 -29 -44 -36 -25 35 190
Consolidated Net Income / (Loss)
-34 -29 -44 -36 -25 35 190
Depreciation Expense
1.22 1.58 1.82 3.48 8.18 20 27
Non-Cash Adjustments To Reconcile Net Income
1.87 1.86 9.18 13 50 39 41
Changes in Operating Assets and Liabilities, net
-1.63 -5.59 3.00 -27 -46 -45 -65
Net Cash From Investing Activities
-61 -42 29 55 -194 -129 -59
Net Cash From Continuing Investing Activities
-61 -42 29 55 -194 -129 -59
Purchase of Property, Plant & Equipment
-0.17 -0.46 -3.52 -12 -152 -130 -59
Acquisitions
- - 0.00 0.00 -42 0.44 0.00
Net Cash From Financing Activities
93 76 1.39 168 400 23 17
Net Cash From Continuing Financing Activities
93 76 1.39 168 400 23 17
Issuance of Debt
- 0.00 0.00 59 445 0.00 0.00
Issuance of Common Equity
97 75 0.42 140 0.96 2.06 3.25
Other Financing Activities, net
0.20 2.48 0.97 5.11 -46 21 14
Effect of Exchange Rate Changes
- 0.80 -0.80 -1.02 0.19 -0.54 1.27
Cash Interest Paid
3.88 3.48 3.33 3.26 8.09 11 11

Quarterly Cash Flow Statements for TransMedics Group

This table details how cash moves in and out of TransMedics Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-45 13 -33 6.56 -27 90 66 22 -8.69 11 20
Net Cash From Operating Activities
-3.44 26 6.86 20 -2.86 92 70 35 25 17 36
Net Cash From Continuing Operating Activities
-3.44 26 6.86 20 -2.86 92 70 35 25 17 36
Net Income / (Loss) Continuing Operations
12 12 4.22 6.86 26 35 24 105 7.32 15 17
Consolidated Net Income / (Loss)
12 12 4.22 6.86 26 35 24 105 7.32 15 17
Depreciation Expense
4.30 4.60 5.18 5.68 6.14 6.73 6.85 7.47 12 10 11
Non-Cash Adjustments To Reconcile Net Income
8.16 8.75 8.71 13 9.73 9.79 10 11 16 14 18
Changes in Operating Assets and Liabilities, net
-28 0.18 -11 -5.83 -44 40 28 -89 -10 -22 -10
Net Cash From Investing Activities
-44 -24 -48 -14 -27 -9.08 -7.62 -16 -37 -7.09 -14
Net Cash From Continuing Investing Activities
-44 -24 -48 -14 -27 -9.08 -7.62 -16 -37 -7.09 -14
Purchase of Property, Plant & Equipment
-44 -24 -48 -14 -27 -9.08 -7.62 -16 -37 -7.09 -8.40
Net Cash From Financing Activities
3.19 11 7.86 1.19 3.03 7.09 3.64 3.10 3.76 0.97 -1.92
Net Cash From Continuing Financing Activities
3.19 11 7.86 1.19 3.03 7.09 3.64 3.10 3.76 0.97 -1.92
Issuance of Common Equity
0.64 - 1.42 - 1.29 - 1.96 - 1.69 - 2.25
Other Financing Activities, net
2.55 11 6.44 1.19 1.74 7.09 1.68 3.10 2.07 0.97 0.84
Effect of Exchange Rate Changes
-0.17 -0.06 0.39 -0.69 0.36 0.81 0.01 0.09 -0.33 -0.25 -0.09

Annual Balance Sheets for TransMedics Group

This table presents TransMedics Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/29/2018 12/28/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
42 105 152 135 277 706 804 1,068
Total Current Assets
35 100 147 119 252 511 497 638
Cash & Equivalents
20 20 25 26 201 395 337 488
Accounts Receivable
3.44 6.56 6.86 5.93 28 64 98 84
Inventories, net
9.28 11 12 15 21 44 47 49
Prepaid Expenses
1.84 1.54 2.33 5.46 2.90 8.03 16 16
Plant, Property, & Equipment, net
3.47 4.79 4.75 9.84 19 174 286 328
Total Noncurrent Assets
3.89 0.51 0.51 6.35 5.63 21 21 103
Noncurrent Note & Lease Receivables
- - - - - - - 0.00
Goodwill
- - - - 0.00 12 12 12
Intangible Assets
- - - - 0.00 2.35 2.15 1.95
Noncurrent Deferred & Refundable Income Taxes
- - - - - - 0.00 84
Other Noncurrent Operating Assets
3.89 0.51 0.51 6.35 5.63 7.11 7.19 5.89
Total Liabilities & Shareholders' Equity
42 105 152 135 277 706 804 1,068
Total Liabilities
48 51 48 67 90 569 575 595
Total Current Liabilities
13 16 12 23 24 55 60 89
Short-Term Debt
- - - - - - 0.00 10
Accounts Payable
4.72 7.25 1.21 6.65 3.34 13 10 10
Accrued Expenses
7.18 8.33 10 16 19 38 45 63
Current Deferred Revenue
0.66 0.54 0.26 0.25 0.24 1.96 1.74 2.91
Other Current Liabilities
- - - 0.00 1.44 2.04 2.73 3.31
Total Noncurrent Liabilities
35 35 36 44 66 514 516 506
Long-Term Debt
34 34 35 35 59 506 509 502
Capital Lease Obligations
- - - - - - - 0.00
Other Noncurrent Operating Liabilities
0.90 - - 8.60 7.42 7.71 6.25 3.58
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-192 55 104 68 187 137 229 473
Total Preferred & Common Equity
-192 55 104 68 187 137 229 473
Preferred Stock
- 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-192 55 104 68 187 137 229 473
Common Stock
144 424 502 510 666 641 697 751
Retained Earnings
-336 -369 -398 -442 -479 -504 -468 -278
Accumulated Other Comprehensive Income / (Loss)
-0.10 -0.00 -0.10 -0.19 -0.23 -0.20 -0.36 0.12

Quarterly Balance Sheets for TransMedics Group

This table presents TransMedics Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
690 689 724 759 786 838 891 946 1,435 1,464 1,518
Total Current Assets
663 537 488 509 492 506 558 613 619 651 692
Cash & Equivalents
582 427 350 363 330 310 401 466 462 473 493
Accounts Receivable
48 61 82 81 90 142 105 81 91 104 115
Inventories, net
31 39 49 49 52 43 39 45 50 54 58
Prepaid Expenses
2.38 9.60 7.61 17 20 10 14 22 17 20 26
Plant, Property, & Equipment, net
20 131 214 229 272 311 312 313 362 365 376
Total Noncurrent Assets
7.74 21 21 20 21 20 20 20 454 448 449
Noncurrent Note & Lease Receivables
- - - - - - - - 335 332 330
Goodwill
- 12 12 12 12 12 12 12 12 12 18
Intangible Assets
- 2.41 2.30 2.25 2.20 2.10 2.05 2.00 0.00 0.00 2.82
Noncurrent Deferred & Refundable Income Taxes
- - - - - - - - 82 79 73
Other Noncurrent Operating Assets
7.74 7.42 6.81 6.48 7.61 6.72 6.54 6.47 25 25 25
Total Liabilities & Shareholders' Equity
690 689 724 759 786 838 891 946 1,435 1,464 1,518
Total Liabilities
545 563 564 569 576 571 572 591 941 946 967
Total Current Liabilities
32 49 50 54 60 56 57 80 92 98 153
Short-Term Debt
- - - - - - - 5.00 15 20 55
Accounts Payable
7.03 13 9.23 13 13 11 9.54 12 11 13 10
Accrued Expenses
23 32 37 38 42 40 42 56 59 59 83
Current Deferred Revenue
0.24 2.63 2.06 1.45 2.18 2.08 1.57 3.31 2.95 3.13 1.50
Other Current Liabilities
1.88 1.99 2.09 2.14 2.54 2.79 3.02 3.24 3.51 3.65 3.64
Total Noncurrent Liabilities
513 514 514 514 516 516 516 511 849 848 814
Long-Term Debt
505 505 507 508 509 510 511 507 498 494 455
Capital Lease Obligations
- - - - - - - - 344 348 352
Other Noncurrent Operating Liabilities
8.46 8.23 7.16 6.60 7.07 5.52 4.91 4.43 6.87 6.40 7.84
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
145 126 159 190 210 266 318 355 494 518 551
Total Preferred & Common Equity
145 126 159 190 210 266 318 355 494 518 551
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
145 126 159 190 210 266 318 355 494 518 551
Common Stock
628 634 651 669 685 709 726 738 765 774 790
Retained Earnings
-482 -508 -492 -479 -475 -443 -408 -383 -271 -256 -239
Accumulated Other Comprehensive Income / (Loss)
-0.22 -0.26 -0.18 -0.24 -0.23 -0.33 0.10 0.10 0.00 -0.21 -0.31

Annual Metrics And Ratios for TransMedics Group

This table displays calculated financial ratios and metrics derived from TransMedics Group's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/28/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - -
Revenue Growth
0.00% 8.62% 18.03% 208.83% 158.53% 82.74% 37.13%
EBITDA Growth
0.00% 19.96% -64.88% 23.03% 73.05% 1,008.05% 112.29%
EBIT Growth
0.00% 15.17% -62.97% 19.52% 51.05% 416.05% 141.69%
NOPAT Growth
0.00% 10.87% -49.44% 20.27% 8.62% 284.82% 417.07%
Net Income Growth
0.00% 14.31% -53.80% 18.06% 30.92% 241.70% 436.58%
EPS Growth
0.00% 50.85% -37.93% 23.13% 37.40% 231.17% 382.18%
Operating Cash Flow Growth
0.00% 6.26% 4.63% -58.73% 71.57% 474.60% 295.14%
Free Cash Flow Firm Growth
0.00% 0.00% -8.70% -122.58% -297.57% 48.39% 183.38%
Invested Capital Growth
0.00% 59.20% -17.88% 323.52% 453.80% 61.41% 23.89%
Revenue Q/Q Growth
0.00% 0.00% 7.23% 30.25% 25.96% 10.09% 6.91%
EBITDA Q/Q Growth
0.00% -1,395.74% -20.65% 18.57% 66.78% 7.98% 12.26%
EBIT Q/Q Growth
0.00% 0.00% -18.68% 15.56% 45.32% 6.57% 13.50%
NOPAT Q/Q Growth
0.00% 0.00% -15.98% 12.64% 24.62% 18.21% 102.70%
Net Income Q/Q Growth
0.00% 0.00% -16.79% 14.10% 30.05% 8.66% 107.37%
EPS Q/Q Growth
0.00% 0.00% -19.40% 17.45% 28.70% 7.45% 97.17%
Operating Cash Flow Q/Q Growth
0.00% 0.41% 1.67% 5.40% 48.64% 30.34% 8.34%
Free Cash Flow Firm Q/Q Growth
0.00% -428.41% -9.08% 11.57% -22.81% 24.08% 16.81%
Invested Capital Q/Q Growth
-56.05% 13.60% -1.42% -8.80% 21.39% 3.32% 24.06%
Profitability Metrics
- - - - - - -
Gross Margin
58.73% 64.88% 69.92% 69.84% 63.77% 59.36% 59.92%
EBITDA Margin
-119.20% -87.83% -122.70% -30.58% -3.19% 15.84% 24.52%
Operating Margin
-125.42% -102.91% -130.29% -33.64% -11.89% 8.49% 17.93%
EBIT Margin
-123.51% -96.46% -133.19% -34.71% -6.57% 11.37% 20.03%
Profit (Net Income) Margin
-142.12% -112.13% -146.11% -38.77% -10.36% 8.03% 31.43%
Tax Burden Percent
100.12% 100.11% 100.08% 100.18% 93.84% 99.12% 176.98%
Interest Burden Percent
114.93% 116.11% 109.61% 111.49% 167.95% 71.29% 88.64%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.88% -76.98%
Return on Invested Capital (ROIC)
-255.61% -175.78% -234.84% -79.32% -13.70% 11.44% 42.78%
ROIC Less NNEP Spread (ROIC-NNEP)
-228.05% -160.84% -212.42% -65.07% 17.94% 10.24% 40.87%
Return on Net Nonoperating Assets (RNNOA)
194.22% 139.52% 183.35% 50.93% -1.72% 7.95% 11.46%
Return on Equity (ROE)
-61.39% -36.27% -51.49% -28.39% -15.42% 19.39% 54.24%
Cash Return on Invested Capital (CROIC)
0.00% -221.46% -215.21% -202.91% -152.52% -35.55% 21.44%
Operating Return on Assets (OROA)
-39.54% -19.22% -28.10% -15.75% -3.23% 6.65% 12.96%
Return on Assets (ROA)
-45.50% -22.34% -30.82% -17.59% -5.09% 4.70% 20.33%
Return on Common Equity (ROCE)
172.63% -36.27% -51.49% -28.39% -15.42% 19.39% 54.24%
Return on Equity Simple (ROE_SIMPLE)
-61.39% -27.67% -65.16% -19.34% -18.24% 15.51% 0.00%
Net Operating Profit after Tax (NOPAT)
-21 -18 -28 -22 -20 37 192
NOPAT Margin
-87.79% -72.03% -91.20% -23.55% -8.32% 8.42% 31.74%
Net Nonoperating Expense Percent (NNEP)
-27.56% -14.95% -22.42% -14.24% -31.64% 1.20% 1.91%
Return On Investment Capital (ROIC_SIMPLE)
- - - -8.94% -3.13% 5.04% 19.50%
Cost of Revenue to Revenue
41.27% 35.12% 30.08% 30.16% 36.23% 40.64% 40.08%
SG&A Expenses to Revenue
99.97% 94.34% 126.51% 74.79% 49.48% 38.19% 30.58%
R&D to Revenue
84.18% 73.45% 73.70% 28.69% 26.18% 12.68% 11.40%
Operating Expenses to Revenue
184.15% 167.79% 200.21% 103.48% 75.66% 50.86% 41.99%
Earnings before Interest and Taxes (EBIT)
-29 -25 -40 -32 -16 50 121
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-28 -23 -37 -29 -7.70 70 148
Valuation Ratios
- - - - - - -
Price to Book Value (P/BV)
7.20 5.20 7.84 10.52 18.78 9.15 8.79
Price to Tangible Book Value (P/TBV)
7.20 5.20 7.84 10.52 20.97 9.74 9.05
Price to Revenue (P/Rev)
16.67 21.08 17.58 21.08 10.66 4.74 6.87
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 59.01 21.85
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 1.69% 4.58%
Enterprise Value to Invested Capital (EV/IC)
42.79 34.83 44.80 40.72 10.81 5.65 8.41
Enterprise Value to Revenue (EV/Rev)
14.70 17.53 15.69 19.56 11.13 5.13 6.91
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 32.38 28.16
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 45.13 34.47
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 60.95 21.76
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 46.42 21.68
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 43.42
Leverage & Solvency
- - - - - - -
Debt to Equity
0.62 0.33 0.52 0.31 3.69 2.23 1.08
Long-Term Debt to Equity
0.62 0.33 0.52 0.31 3.69 2.23 1.06
Financial Leverage
-0.85 -0.87 -0.86 -0.78 -0.10 0.78 0.28
Leverage Ratio
3.01 1.62 1.67 1.61 3.03 4.13 2.67
Compound Leverage Factor
3.46 1.88 1.83 1.80 5.09 2.94 2.37
Debt to Total Capital
38.45% 25.01% 34.15% 23.85% 78.68% 69.02% 51.99%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.01%
Long-Term Debt to Total Capital
38.45% 25.01% 34.15% 23.85% 78.68% 69.02% 50.98%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
61.55% 74.99% 65.85% 76.15% 21.32% 30.98% 48.01%
Debt to EBITDA
-1.21 -1.54 -0.95 -2.05 -65.72 7.28 3.45
Net Debt to EBITDA
1.65 4.04 1.54 4.99 -14.46 2.47 0.16
Long-Term Debt to EBITDA
-1.21 -1.54 -0.95 -2.05 -65.72 7.28 3.38
Debt to NOPAT
-1.65 -1.88 -1.28 -2.67 -25.17 13.70 2.67
Net Debt to NOPAT
2.25 4.93 2.07 6.47 -5.54 4.65 0.13
Long-Term Debt to NOPAT
-1.65 -1.88 -1.28 -2.67 -25.17 13.70 2.61
Altman Z-Score
0.01 3.77 0.26 11.69 2.76 2.77 5.38
Noncontrolling Interest Sharing Ratio
381.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - -
Current Ratio
6.21 12.36 5.11 10.66 9.30 8.30 7.14
Quick Ratio
5.41 11.15 4.23 9.67 8.34 7.25 6.41
Cash Flow Metrics
- - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -23 -25 -56 -224 -116 96
Operating Cash Flow to CapEx
-19,567.27% -6,651.65% -820.23% -384.79% -8.58% 37.61% 325.46%
Free Cash Flow to Firm to Interest Expense
0.00 -5.84 -6.53 -15.11 -20.74 -8.02 6.99
Operating Cash Flow to Interest Expense
-7.42 -7.59 -7.45 -12.30 -1.21 3.39 13.99
Operating Cash Flow Less CapEx to Interest Expense
-7.45 -7.71 -8.36 -15.49 -15.28 -5.62 9.69
Efficiency Ratios
- - - - - - -
Asset Turnover
0.32 0.20 0.21 0.45 0.49 0.58 0.65
Accounts Receivable Turnover
4.72 3.82 4.73 5.57 5.30 5.47 6.65
Inventory Turnover
0.95 0.78 0.68 1.59 2.70 3.95 5.09
Fixed Asset Turnover
5.71 5.37 4.15 6.43 2.50 1.92 1.97
Accounts Payable Turnover
1.63 2.13 2.32 5.64 10.90 15.60 23.51
Days Sales Outstanding (DSO)
77.29 95.55 77.18 65.50 68.87 66.67 54.86
Days Inventory Outstanding (DIO)
383.94 469.22 537.16 229.62 135.19 92.33 71.77
Days Payable Outstanding (DPO)
224.20 171.33 157.52 64.69 33.48 23.40 15.52
Cash Conversion Cycle (CCC)
237.03 393.44 456.82 230.43 170.58 135.60 111.10
Capital & Investment Metrics
- - - - - - -
Invested Capital
8.11 13 11 45 249 401 497
Invested Capital Turnover
2.91 2.44 2.57 3.37 1.65 1.36 1.35
Increase / (Decrease) in Invested Capital
0.00 4.80 -2.31 34 204 153 96
Enterprise Value (EV)
347 450 475 1,828 2,688 2,265 4,181
Market Capitalization
393 541 532 1,970 2,577 2,093 4,157
Book Value per Share
$2.58 $3.83 $2.44 $5.87 $4.20 $6.81 $13.84
Tangible Book Value per Share
$2.58 $3.83 $2.44 $5.87 $3.76 $6.40 $13.45
Total Capital
89 139 103 246 643 738 985
Total Debt
34 35 35 59 506 509 512
Total Long-Term Debt
34 35 35 59 506 509 502
Net Debt
-47 -91 -57 -142 111 173 24
Capital Expenditures (CapEx)
0.17 0.46 3.52 12 152 130 59
Debt-free, Cash-free Net Working Capital (DFCFNWC)
3.20 9.25 3.02 27 61 101 70
Debt-free Net Working Capital (DFNWC)
84 135 95 229 456 437 558
Net Working Capital (NWC)
84 135 95 229 456 437 548
Net Nonoperating Expense (NNE)
13 10 17 14 4.92 1.70 1.88
Net Nonoperating Obligations (NNO)
-47 -91 -57 -142 111 173 24
Total Depreciation and Amortization (D&A)
1.02 2.21 3.17 3.86 8.18 20 27
Debt-free, Cash-free Net Working Capital to Revenue
13.55% 36.06% 9.96% 29.37% 25.21% 22.80% 11.58%
Debt-free Net Working Capital to Revenue
355.39% 526.10% 315.47% 244.63% 188.61% 99.04% 92.24%
Net Working Capital to Revenue
355.39% 526.10% 315.47% 244.63% 188.61% 99.04% 90.58%
Earnings Adjustments
- - - - - - -
Adjusted Basic Earnings per Share
$0.00 ($1.16) ($1.60) ($1.23) ($0.77) $1.07 $5.60
Adjusted Weighted Average Basic Shares Outstanding
0.00 27.37M 27.62M 29.56M 32.52M 33.23M 33.99M
Adjusted Diluted Earnings per Share
$0.00 ($1.16) ($1.60) ($1.23) ($0.77) $1.01 $4.87
Adjusted Weighted Average Diluted Shares Outstanding
0.00 27.37M 27.62M 29.56M 32.52M 35.22M 40.54M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($1.16) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 24.70M 27.96M 32.20M 32.72M 33.66M 34.30M
Normalized Net Operating Profit after Tax (NOPAT)
-21 -18 -28 -22 -20 37 76
Normalized NOPAT Margin
-87.79% -72.03% -91.20% -23.55% -8.32% 8.42% 12.55%
Pre Tax Income Margin
-141.95% -112.00% -145.99% -38.70% -11.04% 8.10% 17.76%
Debt Service Ratios
- - - - - - -
EBIT to Interest Expense
-6.70 -6.21 -10.40 -8.71 -1.47 3.48 8.80
NOPAT to Interest Expense
-4.76 -4.63 -7.12 -5.91 -1.86 2.58 13.94
EBIT Less CapEx to Interest Expense
-6.74 -6.32 -11.31 -11.90 -15.54 -5.52 4.50
NOPAT Less CapEx to Interest Expense
-4.80 -4.75 -8.03 -9.10 -15.94 -6.43 9.64
Payout Ratios
- - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-14.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for TransMedics Group

This table displays calculated financial ratios and metrics derived from TransMedics Group's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - - 34,302,451.00 34,560,911.00 34,675,145.00
DEI Adjusted Shares Outstanding
- - - - - - - - 34,302,451.00 34,560,911.00 34,675,145.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - 0.21 0.42 0.49
Growth Metrics
- - - - - - - - - - -
Revenue Growth
133.07% 117.87% 63.72% 49.83% 48.21% 37.68% 32.24% 32.18% 21.18% 20.70% 41.15%
EBITDA Growth
8,315.79% 598.49% 160.80% 46.66% 78.75% 127.68% 155.93% 99.85% -24.14% -20.52% 26.49%
EBIT Growth
1,142.44% 934.49% 133.69% 41.40% 88.46% 151.38% 237.34% 136.62% -48.05% -32.85% 18.29%
NOPAT Growth
935.98% 2,078.90% 119.64% 212.23% 116.13% 181.10% 531.46% 1,121.94% -56.61% -49.09% -18.97%
Net Income Growth
562.71% 1,318.18% 116.58% 70.11% 110.56% 186.26% 476.83% 1,436.87% -71.52% -57.94% -29.80%
EPS Growth
537.50% 1,266.67% 115.38% 58.33% 100.00% 162.86% 450.00% 1,263.16% -71.43% -55.43% -30.30%
Operating Cash Flow Growth
60.34% 543.18% 199.84% 136.79% 16.89% 256.21% 914.63% 75.52% 959.30% -81.11% -48.25%
Free Cash Flow Firm Growth
-844.11% -687.36% -2.44% 28.26% 50.15% 77.13% 106.82% 105.39% -232.95% -690.95% -4,169.29%
Invested Capital Growth
464.17% 394.88% 89.64% 61.41% 47.44% 27.93% 3.18% 23.89% 90.73% 111.72% 129.37%
Revenue Q/Q Growth
19.31% 18.02% -4.85% 11.83% 18.02% 9.64% -8.61% 11.78% 8.19% 9.21% 6.87%
EBITDA Q/Q Growth
83.27% 0.40% -36.00% 24.55% 123.36% 27.89% -28.06% -2.74% -15.21% 33.99% 14.48%
EBIT Q/Q Growth
114.13% -1.34% -50.16% 34.32% 185.39% 31.59% -33.12% -5.79% -37.35% 70.11% 17.81%
NOPAT Q/Q Growth
350.06% 2.66% -68.96% 117.67% 211.53% 33.53% -30.26% 321.21% -88.94% 56.66% 11.00%
Net Income Q/Q Growth
202.58% -0.02% -65.43% 62.64% 274.54% 35.92% -30.33% 333.34% -93.06% 100.71% 16.29%
EPS Q/Q Growth
191.67% 0.00% -65.71% 58.33% 268.42% 31.43% -28.26% 292.42% -92.28% 105.00% 12.20%
Operating Cash Flow Q/Q Growth
-141.37% 848.70% -73.34% 186.76% -114.52% 3,308.72% -24.05% -50.39% -28.92% -29.45% 108.01%
Free Cash Flow Firm Q/Q Growth
-23.37% -2.71% 29.45% 19.75% 14.27% 52.88% 121.03% -36.58% -5,398.02% -11.93% -8.20%
Invested Capital Q/Q Growth
27.21% 5.90% 15.96% 3.32% 16.20% -8.12% -6.47% 24.06% 78.89% 2.00% 1.33%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
61.91% 60.59% 55.94% 59.21% 61.47% 61.38% 58.80% 58.11% 58.16% 59.59% 58.45%
EBITDA Margin
20.95% 17.83% 11.99% 13.35% 25.27% 29.48% 23.20% 20.19% 15.82% 19.41% 20.79%
Operating Margin
12.83% 10.94% 3.61% 7.11% 19.12% 23.24% 16.20% 13.23% 7.64% 12.50% 13.86%
EBIT Margin
16.51% 13.80% 7.23% 8.68% 21.00% 25.20% 18.44% 15.54% 9.00% 14.02% 15.45%
Profit (Net Income) Margin
12.59% 10.67% 3.88% 5.64% 17.89% 22.18% 16.91% 65.55% 4.21% 7.73% 8.41%
Tax Burden Percent
98.42% 100.34% 99.32% 98.11% 96.27% 96.48% 105.59% 487.14% 86.21% 75.66% 70.84%
Interest Burden Percent
77.50% 77.03% 53.99% 66.18% 88.52% 91.24% 86.84% 86.58% 54.20% 72.87% 76.82%
Effective Tax Rate
1.58% -0.34% 0.68% 1.89% 3.73% 3.52% -5.59% -387.14% 13.79% 24.34% 29.16%
Return on Invested Capital (ROIC)
20.13% 19.57% 4.84% 9.48% 22.97% 31.21% 24.56% 86.89% 6.18% 9.47% 10.83%
ROIC Less NNEP Spread (ROIC-NNEP)
19.86% 18.51% 5.09% 8.33% 22.56% 30.92% 24.30% 88.67% 4.79% 8.15% 9.45%
Return on Net Nonoperating Assets (RNNOA)
1.14% 3.73% 3.89% 6.47% 18.90% 15.54% 9.63% 24.85% 3.75% 4.87% 4.32%
Return on Equity (ROE)
21.27% 23.30% 8.73% 15.95% 41.87% 46.74% 34.19% 111.74% 9.93% 14.33% 15.14%
Cash Return on Invested Capital (CROIC)
-145.12% -133.57% -51.30% -35.55% -25.22% -5.10% 20.90% 21.44% -35.60% -46.13% -52.85%
Operating Return on Assets (OROA)
9.70% 6.83% 3.93% 5.08% 13.13% 16.24% 12.06% 10.05% 5.04% 7.96% 9.13%
Return on Assets (ROA)
7.40% 5.28% 2.11% 3.30% 11.19% 14.29% 11.06% 42.39% 2.35% 4.39% 4.97%
Return on Common Equity (ROCE)
21.27% 23.30% 8.73% 15.95% 41.87% 46.74% 34.19% 111.74% 9.93% 14.33% 15.14%
Return on Equity Simple (ROE_SIMPLE)
-6.39% 1.58% 15.55% 0.00% 18.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
12 13 3.90 8.48 26 35 25 104 11 18 20
NOPAT Margin
12.62% 10.98% 3.58% 6.97% 18.41% 22.42% 17.11% 64.46% 6.59% 9.45% 9.82%
Net Nonoperating Expense Percent (NNEP)
0.27% 1.06% -0.25% 1.14% 0.41% 0.29% 0.25% -1.78% 1.39% 1.31% 1.38%
Return On Investment Capital (ROIC_SIMPLE)
- - - 1.15% 3.40% 4.26% 2.84% 10.52% 0.85% 1.30% 1.41%
Cost of Revenue to Revenue
38.09% 39.41% 44.06% 40.79% 38.53% 38.62% 41.20% 41.89% 41.84% 40.41% 41.55%
SG&A Expenses to Revenue
37.34% 37.53% 39.22% 38.57% 30.39% 28.02% 31.99% 32.00% 36.21% 30.45% 30.21%
R&D to Revenue
11.75% 12.12% 13.12% 13.54% 11.96% 10.13% 10.61% 12.88% 14.30% 16.65% 14.38%
Operating Expenses to Revenue
49.09% 49.65% 52.34% 52.10% 42.35% 38.14% 42.60% 44.87% 50.52% 47.10% 44.59%
Earnings before Interest and Taxes (EBIT)
16 16 7.86 11 30 40 27 25 16 27 31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
20 20 13 16 36 46 33 32 28 37 42
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
15.14 26.13 24.95 9.15 8.50 14.25 10.77 8.79 6.90 4.43 5.25
Price to Tangible Book Value (P/TBV)
16.63 28.17 26.70 9.74 8.96 14.89 11.20 9.05 7.07 4.53 5.46
Price to Revenue (P/Rev)
8.13 13.83 13.06 4.74 4.64 8.53 6.75 6.87 5.36 3.43 3.98
Price to Earnings (P/E)
0.00 1,653.67 160.47 59.01 46.27 63.27 41.68 21.85 19.83 15.13 20.03
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.06% 0.62% 1.69% 2.16% 1.58% 2.40% 4.58% 5.04% 6.61% 4.99%
Enterprise Value to Invested Capital (EV/IC)
8.13 15.25 13.95 5.65 5.29 10.84 9.66 8.41 4.28 2.96 3.55
Enterprise Value to Revenue (EV/Rev)
8.66 14.23 13.50 5.13 5.05 8.74 6.83 6.91 5.98 4.02 4.48
Enterprise Value to EBITDA (EV/EBITDA)
200.26 168.54 83.60 32.38 28.68 41.49 29.26 28.16 27.23 20.62 23.46
Enterprise Value to EBIT (EV/EBIT)
1,562.75 321.21 114.99 45.13 38.31 52.65 36.21 34.47 35.62 28.62 33.07
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 172.26 60.95 48.00 62.71 40.83 21.76 20.94 15.73 19.23
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 215.27 144.64 46.42 49.91 40.29 21.75 21.68 17.28 18.40 29.03
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 46.94 43.42 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
3.18 2.67 2.42 2.23 1.92 1.61 1.44 1.08 1.73 1.66 1.56
Long-Term Debt to Equity
3.18 2.67 2.42 2.23 1.92 1.61 1.43 1.06 1.70 1.62 1.46
Financial Leverage
0.06 0.20 0.76 0.78 0.84 0.50 0.40 0.28 0.78 0.60 0.46
Leverage Ratio
2.87 4.32 4.38 4.13 3.67 3.25 3.06 2.67 2.99 2.82 2.72
Compound Leverage Factor
2.23 3.33 2.37 2.73 3.25 2.96 2.66 2.31 1.62 2.05 2.09
Debt to Total Capital
76.07% 72.78% 70.78% 69.02% 65.70% 61.63% 59.03% 51.99% 63.43% 62.45% 61.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.58% 1.01% 1.11% 1.45% 3.88%
Long-Term Debt to Total Capital
76.07% 72.78% 70.78% 69.02% 65.70% 61.63% 58.45% 50.98% 62.32% 61.00% 57.12%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
23.93% 27.22% 29.22% 30.98% 34.30% 38.37% 40.97% 48.01% 36.57% 37.55% 39.00%
Debt to EBITDA
39.49 16.76 7.85 7.28 5.94 4.56 3.87 3.45 6.13 6.62 6.19
Net Debt to EBITDA
12.21 4.79 2.75 2.47 2.33 0.99 0.34 0.16 2.83 2.99 2.65
Long-Term Debt to EBITDA
39.49 16.76 7.85 7.28 5.94 4.56 3.83 3.38 6.03 6.46 5.80
Debt to NOPAT
-50.94 -311.94 16.17 13.70 9.93 6.90 5.40 2.67 4.72 5.05 5.08
Net Debt to NOPAT
-15.75 -89.08 5.68 4.65 3.89 1.49 0.48 0.13 2.17 2.28 2.17
Long-Term Debt to NOPAT
-50.94 -311.94 16.17 13.70 9.93 6.90 5.34 2.61 4.63 4.93 4.76
Altman Z-Score
2.83 5.61 5.82 2.61 2.99 5.53 4.68 5.09 2.83 2.18 2.55
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
9.72 9.37 8.20 8.30 9.10 9.86 7.69 7.14 6.74 6.63 4.53
Quick Ratio
8.60 8.17 7.00 7.25 8.13 8.93 6.86 6.41 6.01 5.87 3.98
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-248 -255 -180 -144 -124 -58 12 7.77 -412 -461 -498
Operating Cash Flow to CapEx
-7.78% 108.23% 14.23% 144.52% -10.56% 1,009.47% 912.55% 222.46% 66.93% 244.06% 428.62%
Free Cash Flow to Firm to Interest Expense
-68.91 -70.29 -49.68 -40.38 -35.72 -16.76 3.51 2.32 -57.40 -63.76 -68.55
Operating Cash Flow to Interest Expense
-0.95 7.10 1.90 5.51 -0.82 26.35 19.93 10.29 3.42 2.40 4.95
Operating Cash Flow Less CapEx to Interest Expense
-13.23 0.54 -11.43 1.70 -8.64 23.74 17.75 5.66 -1.69 1.41 3.80
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.59 0.50 0.54 0.58 0.63 0.64 0.65 0.65 0.56 0.57 0.59
Accounts Receivable Turnover
4.93 5.58 5.32 5.47 4.36 5.71 6.63 6.65 5.46 6.40 7.44
Inventory Turnover
3.08 3.56 3.56 3.95 4.31 4.88 4.65 5.09 5.58 5.94 5.86
Fixed Asset Turnover
2.54 2.88 1.99 1.92 1.86 1.96 1.94 1.97 1.89 1.97 2.11
Accounts Payable Turnover
16.47 14.05 12.56 15.60 19.97 18.93 17.79 23.51 23.93 24.60 27.01
Days Sales Outstanding (DSO)
74.10 65.46 68.61 66.67 83.72 63.89 55.05 54.86 66.80 57.06 49.07
Days Inventory Outstanding (DIO)
118.53 102.57 102.40 92.33 84.78 74.79 78.42 71.77 65.43 61.47 62.33
Days Payable Outstanding (DPO)
22.16 25.97 29.06 23.40 18.28 19.28 20.52 15.52 15.26 14.84 13.51
Cash Conversion Cycle (CCC)
170.48 142.06 141.95 135.60 150.22 119.40 112.94 111.10 116.98 103.69 97.88
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
316 335 388 401 466 428 401 497 889 907 919
Invested Capital Turnover
1.60 1.78 1.35 1.36 1.25 1.39 1.44 1.35 0.94 1.00 1.10
Increase / (Decrease) in Invested Capital
260 267 184 153 150 94 12 96 423 479 518
Enterprise Value (EV)
2,571 5,106 5,416 2,265 2,465 4,644 3,870 4,181 3,805 2,685 3,262
Market Capitalization
2,414 4,961 5,237 2,093 2,265 4,534 3,825 4,157 3,410 2,296 2,894
Book Value per Share
$4.87 $5.77 $6.29 $6.81 $7.91 $9.40 $10.42 $13.84 $14.40 $14.99 $15.88
Tangible Book Value per Share
$4.43 $5.35 $5.88 $6.40 $7.51 $9.00 $10.02 $13.45 $14.06 $14.66 $15.28
Total Capital
666 698 718 738 776 829 867 985 1,351 1,380 1,412
Total Debt
507 508 509 509 510 511 512 512 857 862 861
Total Long-Term Debt
507 508 509 509 510 511 507 502 842 842 807
Net Debt
157 145 178 173 200 110 46 24 395 389 368
Capital Expenditures (CapEx)
44 24 48 14 27 9.08 7.62 16 37 7.09 8.40
Debt-free, Cash-free Net Working Capital (DFCFNWC)
88 92 102 101 140 101 72 70 81 100 101
Debt-free Net Working Capital (DFNWC)
438 455 432 437 450 502 538 558 542 573 594
Net Working Capital (NWC)
438 455 432 437 450 502 533 548 527 553 540
Net Nonoperating Expense (NNE)
0.03 0.36 -0.32 1.62 0.74 0.37 0.28 -1.75 4.15 3.28 2.86
Net Nonoperating Obligations (NNO)
157 145 178 173 200 110 46 24 395 389 368
Total Depreciation and Amortization (D&A)
4.30 4.60 5.18 5.68 6.14 6.73 6.85 7.47 12 10 11
Debt-free, Cash-free Net Working Capital to Revenue
29.59% 25.70% 25.51% 22.80% 28.71% 19.00% 12.73% 11.58% 12.68% 14.98% 13.94%
Debt-free Net Working Capital to Revenue
147.54% 126.81% 107.81% 99.04% 92.23% 94.39% 95.04% 92.24% 85.29% 85.69% 81.69%
Net Working Capital to Revenue
147.54% 126.81% 107.81% 99.04% 92.23% 94.39% 94.16% 90.58% 82.93% 82.70% 74.16%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.37 $0.37 $0.13 $0.20 $0.76 $1.03 $0.71 $3.10 $0.21 $0.42 $0.49
Adjusted Weighted Average Basic Shares Outstanding
32.76M 33.12M 33.44M 33.23M 33.72M 33.91M 34.11M 33.99M 34.38M 34.58M 34.69M
Adjusted Diluted Earnings per Share
$0.35 $0.35 $0.12 $0.19 $0.70 $0.92 $0.66 $2.59 $0.20 $0.41 $0.46
Adjusted Weighted Average Diluted Shares Outstanding
34.68M 35.29M 35.68M 35.22M 39.91M 40.56M 40.75M 40.54M 36.19M 40.71M 40.83M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
32.94M 33.36M 33.56M 33.66M 33.83M 34.09M 34.17M 34.30M 34.56M 34.68M 34.73M
Normalized Net Operating Profit after Tax (NOPAT)
12 8.76 3.90 8.48 26 35 16 15 11 18 20
Normalized NOPAT Margin
12.62% 7.66% 3.58% 6.97% 18.41% 22.42% 11.34% 9.26% 6.59% 9.45% 9.82%
Pre Tax Income Margin
12.80% 10.63% 3.90% 5.75% 18.58% 22.99% 16.01% 13.46% 4.88% 10.22% 11.87%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
4.44 4.35 2.17 2.96 8.71 11.41 7.60 7.45 2.18 3.69 4.31
NOPAT to Interest Expense
3.40 3.46 1.08 2.37 7.63 10.15 7.05 30.90 1.60 2.49 2.74
EBIT Less CapEx to Interest Expense
-7.83 -2.20 -11.15 -0.85 0.90 8.80 5.41 2.82 -2.93 2.70 3.16
NOPAT Less CapEx to Interest Expense
-8.88 -3.09 -12.25 -1.44 -0.18 7.54 4.86 26.27 -3.51 1.50 1.59
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

TransMedics Group’s financial statements show a business that has expanded rapidly since 2023, with revenue, profitability, assets and cash all substantially higher than several years ago. However, the latest quarter also shows slower cash generation, continued reliance on significant financing obligations and growing working-capital needs.

Revenue growth remains the clearest strength. Quarterly revenue increased from $31.4 million in Q4 2022 to $189.9 million in Q2 2026. On a year-over-year basis, Q2 2026 revenue rose approximately 20.7% from the restated Q2 2025 figure of $157.4 million. Revenue also increased sequentially from $173.9 million in Q1 2026.

Profitability has improved dramatically over the longer term. TransMedics moved from a $7.4 million net loss in Q3 2022 to net income of $14.7 million in Q2 2026. The latest quarter produced a 59.6% gross margin, a 12.5% operating margin and a 7.7% net margin. Operating income also nearly doubled sequentially, from $13.3 million in Q1 to $23.7 million in Q2.

Cash generation is positive, but uneven. Operating cash flow was $17.3 million in Q2 2026, and capital expenditures of $7.1 million resulted in approximate free cash flow of $10.2 million. This was a meaningful improvement from the negative free cash flow recorded in Q1 2026, although it was well below the $82.5 million generated in Q2 2025.

  • Strong long-term revenue trajectory: Quarterly revenue has grown more than sixfold from Q4 2022 to Q2 2026, indicating significant expansion in the company’s commercial operations.
  • Improving profitability: Gross profit reached $113.2 million in Q2 2026, while operating income and net income increased sequentially from Q1 2026.
  • Positive free cash flow in the latest quarter: Operating cash flow of $17.3 million exceeded capital expenditures of $7.1 million, producing approximately $10.2 million of free cash flow.
  • Strong liquidity: Cash and equivalents totaled $472.7 million at June 30, 2026, compared with $98.3 million of current liabilities. This represents substantial short-term balance-sheet flexibility.
  • Asset expansion supports growth: Net property, plant and equipment increased to $365.3 million from $191.6 million in Q1 2023, reflecting continued investment in infrastructure and operating capacity.
  • Improving accumulated losses: Retained earnings improved from a deficit of $507.7 million in Q3 2023 to a deficit of $256.0 million in Q2 2026 as the company generated sustained profits.
  • Working capital remains important: Accounts receivable rose to $104.1 million in Q2 2026 from $90.7 million in Q1. This may reflect higher sales, but investors should monitor collections and the conversion of revenue into cash.
  • Results are affected by restatements: Several 2024 and 2025 comparative income-statement and cash-flow figures are identified as restated, so investors should rely on the latest reported comparative figures when evaluating historical trends.
  • Cash-flow volatility: Operating cash flow declined from $91.6 million in Q2 2025 to $17.3 million in Q2 2026, while Q1 2026 operating cash flow was stronger at $24.5 million. Changes in operating assets and liabilities used $21.6 million of cash in Q2.
  • Significant financing obligations: The balance sheet included $20.0 million of short-term debt, $494.0 million of long-term debt and $347.7 million of capital lease obligations. These obligations total approximately $861.7 million, exceeding cash and equivalents by roughly $389.0 million before considering other assets or liabilities.

The overall trend remains favorable: TransMedics is growing quickly, has moved decisively into sustained profitability and maintains a sizable cash balance. The principal risks are whether cash conversion can keep pace with reported earnings and whether the company can support its debt and lease obligations while continuing to invest for growth.

11/19/26 03:23 PM ETAI Generated. May Contain Errors.

TransMedics Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, TransMedics Group's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

TransMedics Group's net income appears to be on an upward trend, with a most recent value of $190.29 million in 2025, compared with -$33.55 million in 2019. The previous period was $35.46 million in 2024. See TransMedics Group's forecast for analyst expectations on what's next for the company.

TransMedics Group's total operating income in 2025 was $108.58 million, based on the following breakdown:
  • Total Gross Profit: $362.81 million
  • Total Operating Expenses: $254.22 million

Over the last 6 years, TransMedics Group's total revenue changed from $23.60 million in 2019 to $605.49 million in 2025, a change of 2,465.2%.

In the past 13 quarters, TransMedics Group's cash and equivalents has ranged from $310.14 million in Q1 2025 to $582.21 million in Q2 2023, and is currently $492.96 million as of their latest financial filing in Q3 2026.

TransMedics Group had total debt of $512.39 million at the end of 2025, a 0.6% increase from 2024, and a 1,400.6% increase since 2019.

Over the last 6 years, TransMedics Group's book value per share changed from 2.58 in 2019 to 13.84 in 2025, a change of 436.1%.



Financial statements for NASDAQ:TMDX last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners